CureVac’s Collaboration with GSK

Baker McKenzie advised CureVac on the deal. CureVac N.V., a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), restructured its existing collaboration...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

CureVac’s Collaboration with MD Anderson

Baker McKenzie advised CureVac N.V. on the deal. CureVac N.V., a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), entered into a...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Tubulis GmbH’s Series B2 Financing

Baker McKenzie advised EQT Life Sciences on the deal. EQT Life Sciences successfully closed a EUR 128 million (USD 138.8 million) Series B2 financing of Tubulis GmbH....

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

CTS Corporation’s Acquisition of Maglab AG

Baker McKenzie advised CTS Corporation on the deal. CTS Corporation executed the acquisition of Swiss-based maglab AG, a company with expertise in magnetic system design, primarily focused on...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here